With the recent approval of mirikizumab for Crohn’s disease and guselkumab for UC, I’ve updated the tables on the website 📊 Thanks to one of your suggestions, they now include the update date 📅. I appreciate your help in improving the content! 🙌 🔗 ibd-eii.com/ibdcheatsheet

Perspiration calprotectin—graph below shows active disease versus remission. Lots of promise in biomarker studies! This could help providers assess patients & stay one step ahead by predicting a flare that may be on the horizon. #CCCongress25 Crohn's & Colitis Foundation

We are looking for Healthcare professionals and people with IBD to contribute to a survey study to better understand what research is needed for treating people with advanced therapies in IBD care. For more information, please visit: forms.office.com/e/SVaNgVwrfp #IBD #Research

It’s here! We sat down with Dr. Katerina Chatzi & Dr. Jasper E. Neggers of Promakhos Therapeutics, the biotech startup awarded a $100K grant from Propel a Cure last year. Listen to this exciting update about their cutting-edge study on what they believe to be a deficiency in the

We are 🚨 ready for #ECCO‼️ #Berlin 2025 🇩🇪 ☄️ 🆕 #IBD article in UEGJ 👉🏼tinyurl.com/37tf2n3r Compared to the gen pop, patients with paediatric-onset #IBD have a ⬆️ 🎓📖 level ⬆️ likely to work 🏥⚕️👩🏼‍⚕️ and public sectors. 🟢 my_UEG 🔵 Y-ECCO 🔴 #GITwitter

Post #ECCO2025 🚨 🆕 #IBD 🔬 Serum collagen biomarkers reflect fibroblast activity in UC & predict ustekinumab response! 🔗 Read more: tinyurl.com/4whx855s #IBD #UlcerativeColitis #CrohnsDisease #Biomarkers #UEGJ 🧬 Key findings: ⬇️⬇️⬇️⬇️

Microplastics are everywhere, and emerging evidence found they accumulate in arteries, the brain, and gut 💡 New findings suggest a novel link between microplastic accumulation and worse #Crohnsdisease outcomes ✅ The more microplastics present in the intestines and mesenteric

Thank you for this great news! Congrats to the #IBD community on another milestone. Propel a Cure for Crohn’s Disease never disappoints! 💜

On Monday 10 March we were in the Amsterdam UMC hospital to record and film four new METHYLOMIC Matters podcasts and videos for patients with Crohn’s Disease, Rheumatoid Arthritis or Psoriasis. The podcasts and videos are also interesting for the general public.

Ashwin,M.D highlights the importance of looking for consistency across studies exploring the role of fiber in IBD outcomes If you're interested in how nutritional therapies alongside medications improve IBD, follow Nutritional Therapy for IBD #GMFH2025

Thank you for this study and for shedding more light on the impact of setons on outcomes in perianal fistulas. It’s interesting how some long-standing practices may not always yield the expected results. I hope we see more research that brings relief and leads to better

Our study on how diet may regulate the gut phageome-bacteriome interaction relaying to a disease protection, #IBD, is freshly out at Gut Journal gut.bmj.com/content/early/…

Think that meds are all that matter for ulcerative colitis? Think again. In our 4-year PREdiCCt study of 2,500 people, we uncovered three game-changers for flare risk: meat intake, mood, and moving more. It’s time to look beyond just drugs—catch the full story in the video

📣Big news! Propel a Cure has pledged $100,000 to support a groundbreaking 2-year Crohn’s disease study at the Ghosh Lab at UC San Diego. This cutting-edge research could uncover new treatments that target the root causes of Crohn’s, not just symptoms. Visit

🚨 Landmark publication alert! 🌍 A big step forward in the complex world of perianal disease and IBD: the first diagnostic criteria for isolated perianal Crohn’s disease (#ipCD), from the TOpClass consortium. A move toward earlier diagnosis & standardised care. 👏 Congrats to

We’re back with another poster at #DDW2025! 🧪 Phenotypic screening for epithelial repair in IBD 📅 May 5 | 12:30–1:30 PM PT 👤 Presenter: Jarrett Bliton 📍 Stop by Booth #4757! 🔗hubs.ly/Q03jY3j80 #GastroResearch #IBD #RepliGut

🌎 Today, on World IBD Day, I am raising awareness for an often overlooked and underrecognized condition in IBD: bile acid malabsorption (BAM). Timely diagnosis and the use of current treatments, such as dietary interventions and medications, are crucial in improving quality of

Thanks to your support, THREE Propel a Cure sponsored research projects are challenging the status quo & offering real hope for better treatments—and a cure—for #crohnsdisease. On Propel a Cure Giving Day and #WorldIBDDay, your gift fuels the kind of bold, outside-the-box

We need your help to gain a greater perspective on this topic, please help us with your insights This would be much appreciated

🔬A very interesting research poster presented at the #ECCO2025 conference in Berlin this year by Van der Kruk et al. highlighted microbially conjugated bile acids (MCBAs) as potential biomarkers for dietary therapy outcomes in pediatric patients with Crohn’s disease. ❗️In